Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots

被引：23

作者：

Dargaud, Y. ^{[1
,2
]}

Prevost, C. ^{[1
]}

Lienhart, A. ^{[1
]}

Bordet, J. Claude ^{[2
]}

Negrier, C. ^{[1
,2
]}

机构：

[1] Hop Edouard Herriot, Unite Hemostase Clin, F-69003 Lyon, France

[2] Univ Lyon 1, Unite Rech Hemophilie, EA 4174, F-69365 Lyon, France

来源：

HAEMOPHILIA | 2011年 / 17卷 / 06期

关键词：

fibrin clot structure; recombinant factor VIIa; thrombin generation test; thromboelastography; t-PA; HEMOPHILIA PATIENTS; INHIBITORS; PLASMA; CAPACITY; FEIBA;

D O I：

10.1111/j.1365-2516.2011.02526.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

. It has been reported that thrombin generation test (TGT) may be a useful tool to monitor recombinant factor VIIa (rFVIIa). However, TGT does not reflect the stability of fibrin clot and its resistance to fibrinolysis which are crucial. Using whole-blood thromboelastography (TEG) and tissue plasminogen activator (tPA), we developed an in-vitro model to assess fibrin clot stability. Fibrin fibres were thicker in haemophiliacs compared with controls (P < 0.0001). After addition of rFVIIa 90 mu g kg-1, the diameter of fibrin fibres was dramatically decreased (P = 0.006). TEG-tPA assay showed a dose-dependent improvement of clot stability in the presence of rFVIIa. These data demonstrate a significant correlation between fibrin clot structure and its stability (P = 0.001). We also showed a correlation between thrombin generating capacity and clot resistance to fibrinolysis. Despite this overall correlation, a relatively large spreading around a general trend was observed, suggesting that the two assays bring complementary information on the haemostatic effect of rFVIIa.

引用

页码：957 / 961

页数：5

共 19 条

[1] Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B [J].

Dargaud, Y ;

Béguin, S ;

Lienhart, A ;

Al Dieri, R ;

Trzeciak, C ;

Bordet, JC ;

Hemker, HC ;

Negrier, C .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (03) :475-480

[2]

Dargaud Y, 2006, HAEMATOLOGICA, V91, P17

[3] Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII [J].

Dargaud, Yesim ;

Bordet, Jean-Claude ;

Lienhart, Anne ;

Negrier, Claude .

SEMINARS IN HEMATOLOGY, 2008, 45 (02) :S72-S73

[4] Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study [J].

Dargaud, Yesim ;

Luddington, Rodger ;

Gray, Elaine ;

Negrier, Claude ;

Lecompte, Thomas ;

Petros, Sirak ;

Hogwood, John ;

Bordet, Jean-Claude ;

Hogwood, John ;

Bordet, Jean-Claude ;

Regnault, Veronique ;

Siegemund, Annelie ;

Baglin, Trevor .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) :303-309

[5] Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery [J].

Dargaud, Yesim ;

Lienhart, Anne ;

Negrier, Claude .

BLOOD, 2010, 116 (25) :5734-5737

[6] Calibrated automated thrombin generation measurement in clotting plasma [J].

Hemker, HC ;

Giesen, P ;

Al Dieri, R ;

Regnault, V ;

de Smedt, E ;

Wagenvoord, R ;

Lecompte, T ;

Béguin, S .

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (01) :4-15

[7] Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A [J].

Lisman, T ;

Mosnier, LO ;

Lambert, T ;

Mauser-Bunschoten, EP ;

Meijers, JCM ;

Nieuwenhuis, HK ;

de Groot, PG .

BLOOD, 2002, 99 (01) :175-179

[8] Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma [J].

Livnat, T. ;

Martinowitz, U. ;

Zivelin, A. ;

Seligsohn, U. .

HAEMOPHILIA, 2008, 14 (04) :782-786

[9] Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors [J].

Martinowitz, U. ;

Livnat, T. ;

Zivelin, A. ;

Kenet, G. .

HAEMOPHILIA, 2009, 15 (04) :904-910

[10]

Nagashima M, 2002, J CLIN INVEST, V109, P101, DOI 10.1172/JCI12119

← 1 2 →